title: [The use of BCG vaccine for preventing recurrences of superficial bladder cancer].
abstract: Responses to immunoprophylaxis of superficial bladder cancer in 94 post-transurethral resection patients were analyzed. Once-a-week intravesicular instillations of BCG vaccine in a dose 100 mg diluted in 50 ml of physiological solution were initiated 30 days after transurethral resection. The main course of therapy comprised 8 instillations made outpatiently. Subsequently the patients underwent a maintenance immunoprophylactic course once a month in the same dose (100 mg) for a year since transurethral resection. 3 years after therapy gave rise to the tumor recurrences in 12 (12.8%) out of 94 patients contrary to 37 (43.0%) patients out of 86 patients. BCG is able to prevent recurrences of superficial bladder cancer subjected to transurethral resection in the majority of patients.
authors.forename: V N
authors.initials: VN
authors.lastname: Tkachuk
authors.forename: A Kh
authors.initials: AKh
authors.lastname: al-Shukri
authors.forename: F
authors.initials: F
authors.lastname: al-Khani
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D000075202:Contraindications; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D009367:Neoplasm Staging; D011182:Postoperative Care; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine
vernacular_title: Primenenie vaktsiny BTsZh dlia profilaktiki retsidivov poverkhnostnogo raka mochevogo puzyria.